Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?

Wallis, Whitney; Qazilbash, Muzaffar H.

doi:10.5500/wjt.v7.i5.250

Cited by 13 publications

(14 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these, G-CSF alone is a favored mobilization strategy. 6 To obtain an optimal PBSC yield, there have been many efforts to improve the efficiency of PBSC collection, such as G-CSF in combination with chemotherapy or chemokine receptor antagonists, as well as increasing the dose or frequency of G-CSF, or changing its administration schedule. [7][8][9][10][11][12][13][14][15] However, there remain limited data regarding the optimal initiation schedule of apheresis or administration schedule of G-CSF for mobilization.…”

Section: Resultsmentioning

confidence: 99%

Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis

et al. 2019

View full text Add to dashboard Cite

BACKGROUND This study evaluated the correlation between the pharmacokinetics and pharmacodynamics of granulocyte colony‐stimulating factor (lenograstim) and the impact of initiation time of apheresis on stem cell mobilization in patients with multiple myeloma. STUDY DESIGN AND METHODS Twenty‐four patients with multiple myeloma were randomized into one of the two groups (early vs. late). Lenograstim at 10 μg/kg/day once daily was injected for at least 4 consecutive days. Apheresis was initiated 2 hours after the fourth dose of lenograstim in the early collection group and 16 hours after the fourth dose of lenograstim in the late collection group. Blood sampling for pharmacokinetics was performed within 30 minutes before, and 1, 2, 6, and 24 hours after the fourth dose of lenograstim. RESULTS Overall, the two groups (early vs. late, n = 10 vs. 14) exhibited similar baseline characteristics including age, sex, subtype of myeloma, stage distribution, and myeloma‐associated symptoms. No correlation was found between plasma lenograstim concentration and peripheral blood (PB) CD34+ cell counts or hematopoietic progenitor cells. In the late collection group, the median number of apheresis procedures for minimal collection was significantly lower (early vs. late: 2 vs. 1; p = 0.04) and there was a higher number of total collected PB CD34+ cells in a single session of apheresis (1.4 vs. 3.1; p = 0.06). There were no differences in median overall PB stem cell collection efficiency. CONCLUSION Late collection positively impacted the number of apheresis procedures for minimal collection, with numerically improved PB stem cell collection efficiency at first apheresis in patients with multiple myeloma.

show abstract

Section: Resultsmentioning

confidence: 99%

Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Therefore, an attempt to collect PBSC for at least two aHSCT should be considered. Mobilization with chemotherapy (e.g., intermediate doses of cyclophosphamide) and granulocyte-colony stimulating factor (G-CSF) is standard in most transplant centers and provides higher stem cell yields in fewer apheresis procedures at the cost of increased toxicity and less predictable onset date of apheresis in comparison with G-CSF mobilization only [9,10]. On the other hand, G-CSF only mobilization fails to achieve the target doses of PBSC in 5-30% of patients [8,11,12,13].…”

Section: Introductionmentioning

confidence: 99%

“…Known factors affecting stem cell mobilization are age, advanced disease status, extensive treatment, thrombocytopenia, prior exposure to irradiation, and alkylating agents [10]. Novel induction regimens using proteasome inhibitors (PI) and especially immunomodulatory drugs (IMIDs) might impact the ability to mobilize and harvest stem cells [14,15].…”

Section: Introductionmentioning

confidence: 99%

“…In case of lenalidomide, a second generation IMID, there are data supporting its adverse impact on mobilization after prolonged treatment. However, there is no clear evidence of bortezomib impact on stem cell harvest [8,10]. In the IFM 2005/01 trial comparing bortezomib and dexamethasone (VD) with vincristin, adriamycin, and dexamethasone (VAD), a trend to lower stem cells yields was observed in patients receiving bortezomib [12,16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization

Škerget

Skopec

Sever

2020

Acta Haematologica Polonica

View full text Add to dashboard Cite

Triplet induction regimens are standard of care for newly diagnosed transplant eligible multiple myeloma patients. The combinations of bortezomib and dexamethasone with either cyclophosphamide (VCD) or thalidomide (VTD) are widely used. There are no data available on the impact of the two regimens on stem cell harvest by using G-CSF only mobilization. In this study, we retrospectively analyzed data from our national registry. The outcome measures were mobilization failure, CD34+ cell counts on collection day, number of apheresis procedures, and the number of collected cells. Overall, 72 patients were treated with either VCD or VTD. The mobilization failure rates were 7% and 9% (p = 0.771) and the total number of collected stem cells were 7.0 × 106 and 6.7 × 106 per kg body weight (p = 0.710) for VCD and VTD, respectively. We found no statistically significant difference between the treatment groups in the outcome measures. The addition of thalidomide to bortezomib and dexamethasone (VTD) does not adversely affect stem cell harvest in patients mobilized with G-CSF only.

show abstract

“…Another important feature of this case is that stem cells could be collected after 26 cycles of lenalidomide treatment. It is known in the literature that lenalidomide treatment, especially 4 cycles and above, is a risk factor for mobilization failure [9]. However, this is not a rule, and stem cell harvesting may be attempted in patients who have received 4 cycles and above with lenalidomide therapy.…”

mentioning

confidence: 99%

A Case with Hepatic Involvement Mimicking Metastatic Disease in Multiple Myeloma

Erciyestepe

Tiryaki

Hindilerden

et al. 2020

Case Reports in Hematology

View full text Add to dashboard Cite

Multiple myeloma is a type of plasma cell disorder and can be seen in different forms. According to current knowledge, it is not a curable disease. Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder and distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma. We present a 53-year-old female patient who started with SMM which turned into multiple myeloma after four years. Despite 26 cycles of lenalidomide treatment, we performed the second autologous stem transplantation. After 12 years from the diagnosis of the disease, it was transformed into plasma cell leukemia and widespread nodular lesions were seen in the liver. Different presentations could be seen due to malignant plasma cell infiltrations or primary amyloidosis. Liver involvement is one of them and is less common than other organ involvement. We report a case of myeloma presenting with extensive nodular involvement in the liver and misdiagnosed as metastatic disease. It is important because of its rarity and change of the treatment approach.

show abstract

Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?

Cited by 13 publications

References 84 publications

Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis

Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis

VTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization

A Case with Hepatic Involvement Mimicking Metastatic Disease in Multiple Myeloma

Contact Info

Product

Resources

About